These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28314298)

  • 1. Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
    Yoshikawa S; Kiyohara Y; Otsuka M; Kondou R; Nonomura C; Miyata H; Iizuka A; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Sugino T; Mochizuki T; Yamaguchi K; Akiyama Y
    Anticancer Res; 2017 Mar; 37(3):1321-1328. PubMed ID: 28314298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPE.
    Kiyohara Y; Yoshikawa S; Otsuka M; Kondou R; Iizuka A; Nonomura C; Ohshima K; Urakami K; Kusuhara M; Nagashima T; Sugino T; Yamaguchi K; Akiyama Y
    J Dermatol; 2017 Oct; 44(10):1156-1159. PubMed ID: 28452169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response-associated gene analysis of 1,000 cancer patients using whole-exome sequencing and gene expression profiling-Project HOPE.
    Akiyama Y; Kondou R; Iizuka A; Ohshima K; Urakami K; Nagashima T; Shimoda Y; Tanabe T; Ohnami S; Ohnami S; Kusuhara M; Mochizuki T; Yamaguchi K
    Biomed Res; 2016; 37(4):233-42. PubMed ID: 27544999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis.
    Akiyama Y; Kiyohara Y; Yoshikawa S; Otsuka M; Kondou R; Nonomura C; Miyata H; Iizuka A; Ashizawa T; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Sugino T; Yamaguchi K
    Oncol Rep; 2018 Mar; 39(3):1125-1131. PubMed ID: 29286146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
    Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
    PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAC1 P29S regulates PD-L1 expression in melanoma.
    Vu HL; Rosenbaum S; Purwin TJ; Davies MA; Aplin AE
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):590-8. PubMed ID: 26176707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
    Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
    Kluger HM; Zito CR; Barr ML; Baine MK; Chiang VL; Sznol M; Rimm DL; Chen L; Jilaveanu LB
    Clin Cancer Res; 2015 Jul; 21(13):3052-60. PubMed ID: 25788491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 inhibition in congenital pigment synthesizing metastatic melanoma.
    Weyand AC; Mody RJ; Rabah RM; Opipari VP
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28675691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
    Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
    Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab in previously untreated melanoma without BRAF mutation.
    Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
    N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
    Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
    Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
    Seremet T; Koch A; Jansen Y; Schreuer M; Wilgenhof S; Del Marmol V; Liènard D; Thielemans K; Schats K; Kockx M; Van Criekinge W; Coulie PG; De Meyer T; van Baren N; Neyns B
    J Transl Med; 2016 Aug; 14(1):232. PubMed ID: 27484791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines.
    Hertzman Johansson C; Azimi A; Frostvik Stolt M; Shojaee S; Wiberg H; Grafström E; Hansson J; Egyházi Brage S
    Melanoma Res; 2013 Oct; 23(5):360-5. PubMed ID: 23921446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Gosho M; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
    J Dermatol Sci; 2017 Nov; 88(2):225-231. PubMed ID: 28736218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
    Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A
    Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status.
    Gangadhar TC; Schuchter LM
    JAMA Oncol; 2015 Jul; 1(4):427-8. PubMed ID: 26181246
    [No Abstract]   [Full Text] [Related]  

  • 20. Nivolumab success in untreated metastatic melanoma.
    Wilkinson E
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.